Tag:
Charles Grassley
Latest Headlines
Latest Headlines
Senate probes ties among narcoticsmakers, pain organizations
The Senate Finance Committee launched an investigation yesterday into the ties among companies that sell pain drugs, pain experts, patient advocacy groups and professional organizations, The New York Times reports.
NYT: Psych text ghostwritten by pharma
Two doctors who've previously drawn scrutiny for failing to disclose financial ties to the drug industry are now under fire for publishing a treatment text that may have been ghostwritten by
GAO joins FDA in congressional spotlight
The FDA's Office of Criminal Investigation is now joined in the congressional spotlight by the Government Accountability Office, which had been sent to investigate it. The case provides a rare
Should FDA split safety ops from CDER?
There's been a move afoot for some time to separate the FDA's drug-safety operations from the Center for Drug Evaluation and Research, which now oversees both drug approvals and safety. The thinking
Grassley's key pharma investigator jumps ship
Drugmakers could well be rejoicing at the news that Paul Thacker, an investigator for Sen. Chuck Grassley (R-Iowa) who led some high-profile pharma probes, is leaving to join a non-profit group.
Grassley zeroes in on pharma whistleblowers
Sen. Charles Grassley (R-Iowa) is on the pharma warpath again. He has written 16 drugmakers, asking them to detail how they deal with whistleblowers who file complaints under the False Claims Act.
Grassley report calls for ghostwriting restrictions
A new congressional report urges a crackdown on ghostwriting, calling on medical journals, medical schools and the NIH to take additional measures to ensure the integrity of scientific articles many
FDA may halt Avandia-Actos trial on safety concerns
The FDA may call the head-to-head study of GlaxoSmithKline's ( NYSE: GSK ) Avandia diabetes drug to a halt on worries about safety. And if the agency does put a stop to the TIDE trial--which pits
Grassley asks AMA, others for payment data
Sen. Charles Grassley has sent letters to 33 industry groups--including the American Medical Association and American Cancer Society--requesting that the organizations reveal industry funding. The
Why isn't ghostwriting plaigiarism, Grassley asks
Sen. Charles E. Grassley wrote to 10 top medical schools Tuesday to ask what they are doing about professors who put their names on ghostwritten articles in medical journals--and why that practice
